申请人:ANTIBIOTX A/S
公开号:US20180207179A1
公开(公告)日:2018-07-26
The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by
Clostridium
bacteria, particularly a
C. difficile
infection. The halogenated salicylanilides are expected to be useful in the treatment of
C. difficile
associated diseases including
C. difficile
associated diarrhoea and
C. difficile
associated colitis.